Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma

Allergy. 2007 Feb;62(2):149-53. doi: 10.1111/j.1398-9995.2006.01310.x.


Background: The health, economic and societal burden of asthma is considerable, and is greatest in patients with severe asthma, particularly when inadequately controlled. Real-life studies that assess the effectiveness of treatment are of particular interest.

Methods: We determined the incremental cost-effectiveness ratio (ICER) of adding omalizumab to standard therapy using data from the real-life 1-year randomized open-label study (ETOPA) and using Canada as a reference country. Only patients receiving high-dose ICS plus LABA were included in the analysis, reflecting the EU label for omalizumab. Costs and quality-adjusted life years (QALYs) gained were used to calculate the ICER for omalizumab (cost/QALY). Probabilistic sensitivity analysis was performed to determine the 95% confidence interval and one-sided sensitivity analyses were performed.

Results: The base case lifetime analysis of standard therapy vs standard therapy plus add-on omalizumab for the first 5 years, gave an ICER of 31,209 Euro. Probabilistic sensitivity analysis indicated that the 95% confidence interval around the ICER was 27,739-40,840 Euro. The ICER range for one-way sensitivity analyses was 23,762 Euro without discounting to 66,443 Euro without inclusion of asthma-related mortality.

Conclusions: This study demonstrates that add-on omalizumab therapy is cost-effective in patients with severe persistent allergic asthma.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Asthmatic Agents / economics*
  • Anti-Asthmatic Agents / therapeutic use*
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Asthma / drug therapy*
  • Asthma / economics*
  • Asthma / immunology
  • Cost-Benefit Analysis
  • Drug Costs
  • Humans
  • Immunoglobulin E / immunology
  • Markov Chains
  • Models, Economic
  • Omalizumab
  • Treatment Outcome


  • Anti-Asthmatic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Omalizumab
  • Immunoglobulin E